Research progress in the treatment of acute radiation sickness with thrombopoietin receptor agonist romiplostim
Acute radiation sickness(ARS)is a systemic syndrome caused by exposure to large doses of radiation in a single or short period of time.Hematopoietic tissue injury is the basic injury in case of acute radiation sickness.Romiplostim(RP)is a thrombopoietin receptor agonist that promotes platelet production by stimulating bone marrow megakaryocytes.In recent years,studies have shown that RP has a significant effect on acute radiation sickness,and has been approved by the United States Food and Drug Administration(FDA)for the treatment of bone marrow acute radiation sickness.In this paper,the recent research progress in the treatment of acute radiation sickness with romiplostim is reviewed.
国家科技期刊平台
NSTL
万方数据
